anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject compound excellent in storage stability, easy in handleability, and useful as a medicine for treating or preventing diseases caused by the abnormal absorption, transport or metabolism of calcium. SOLUTION: This vitamin D derivative of crystal form is represented by formula I. The derivative can be obtained by applying a crystallization treatment to a vitamin D derivative of amorphous form represented by formula II in an organic solvent containing water. For example, 10mg of the vitamin D derivative of amorphous form represented by formula II is dissolved in 0.2ml of diethyl ether, and the obtained solution is mixed with 1.35ml of toluene and subsequently stirred, until giving a homogeneous solution. The homogeneous solution is concentrated under vacuum, until being reduced to a half volume of the solution, mixed with three drops (approximately 100mg) of purified water and further stirred at room temperature for &gt;=15hr. The treated solution is cooled to approximately 5 deg.C, and the deposited crystals are filtered off to obtain 7mg of the vitamin D derivative or crystal form.
PURPOSE: To produce crystalline dry powder contg. no foreign matter by adding an org. solvent which is easy to dissolve in water and is hard to dissolve in org. compounds and an org. solvent which is hard to dissolve in water to an aq. crystalline org. compound soln. for medical use, and dispersing, cooling and freeze-drying these.  
     CONSTITUTION: First, an org. solvent which is easy to dissolve in water and is hard to dissolve in crystalline org. compound, for example, methanol or the like, and an org. solvent which is hard to dissolve in water, for example, dichloromethane or the like are added into an aq. soln. of a crystalline org. compound, for example, sodium cephapyrine under sterile operation. Thence, an org. solvent which is hard to dissolve in water is dispersed thoroughly in an aq. soln. of the crystalline org. compound. This treating soln. is filled in a vial and is quickly cooled to about ≤-30°C in a freeze dryer, after which it is heated slowly up to about -20W-5°C, whereby the crystallization is completed. Further, if it is cooled to about -40°C or around the same and vacuum drying is progressed carefully under elevation of tray temp., the product of the crystalline powder contained in the vial is obtained. 
     COPYRIGHT: (C)1982,JPO&amp;Japio
FIELD: medicine.SUBSTANCE: method involves the nasoenteric administration ofTc-pertechnetate into a small intestine at 1.0-14 MBq/kg diluted with normal saline to an amount of 20 ml. That is immediately followed by a dynamic scintigraphy by means of two-detector rotation gamma-chamber for 60 minutes with a gamma-chamber detection mounted above a projection of the intestine and liver. Following the examination results enables calculated an absorption coefficient of a radiopharmaceutical agent (K); thereafter the scintigraphy is continued in the mode of &#34;The Whole Body&#34;, which provides a basis to determine a percentage of the radiopharmaceutical agent (A) absorbed from an intestinal lumen. If the absorption coefficient is less than 3 and the absorption is less than 50% from the administered radiopharmaceutical agent, the small intestinal malabsorption is stated. K is described by the scintigram forming the sharpest image of the liver and having an area of interest 100 pxls to be marked within a liver, which is followed by constructing an activity/time curve. K is calculated as a slope of the curve to a horizontal axis with using the first 4 minutes of the linear rise of the curve by formula: K=(y-y)/(t-t)×60, wherein K is the absorption coefficient, tand tare time distances, seconds; yis a pulse count within the time distance t, yis a pulse count within the time distance t. To calculate A, an area including the whole patient&#39;s body and an area covering the visualised enteric loops are marked on the scintigram. The calculation follows the formula: A=(n(b)-n(e))/n(e)×100%, wherein n(b) is the total pulse count recorded within the whole body; n(e) is the total pulse count recorded within the small intestine.EFFECT: method provides the high information value of the examination ensured by the complex analysis of the enteric function parameters in the early postoperative period.3 cl, 3 dwg, 1 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antibody which can be used for diagnosis, prognosis, and effective treating of cancer especially of metastatic cancer.  &lt;P&gt;SOLUTION: The invention discloses as follows. The identifying and formation of the antibody which is specifically combined to a TMEFF2 protein in connection with cancer. The antibody is an antibody combined with a fluorescent label, radioisotope, and effector component chosen from the group consisting of a cytotoxicity chemical substance (auristatin). Moreover, the antibody is an antibody fragment or humanized antibody, and is an antibody chosen from the group consisting of antibodies which are produced by a cell line which has an ATCC accession number of PTA-4127. A pharmaceutical composition especially useful in order to treat prostate cancer.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
Immunoglobulin light chain proteins are used to generate synthetic fibrils  in vitro . The fibrils are mixed with immunoglobulin light chain proteins from a biological sample. In either a direct binding assay, competition assay, or dilution-based competition assay, a signal is detected from the mixture. The intensity of the detectable signal relates to the level of binding between the immunoglobulin light chain proteins to the fibrils and can thus be used to identify amyloidogenic immunoglobulin light chain proteins in a biological sample of the subject and to assess amyloidogenic risk to a subject. For example, the signal intensities from the assays can be used in a comparison to one or more threshold (control) values derived from samples of known light chain types or in the absence of light chains. The comparisons permit identification of amyloidogenic proteins, assessment of amyloidogenic risk, and categorization of the subject into an appropriate &#34;at risk&#34; group.
Vaccines of live rabies virus are produced by culturing chick-or chick eggadapted rabies virus in a growth medium containing chick embryo cells and subsequently harvesting the virus, at least the last propagation step being carried out while the chick embryo cells are maintained in a synthetic protein-free maintenance medium, e.g. Medium 199, Healy&#39;s synthetic medium No. 858 or Eagle&#39;s basal medium. It is essential that the rabies virus employed in the last propagation step should be subjected to one or more dilution passages in a chick embryo culture in a synthetic protein free maintenance medium.  Trypsinized chick embryo cells were cultured in a growth medium, e.g. solution of lactalbumin hydrolysate in Earle&#39;s basic salt solution fortified with animal serum and containing antibiotics at 35 DEG C. for 1 to 2 days.  The growth medium was decanted from the cell sheets which were washed with a synthetic maintenance medium, e.g.  Medium 199, and inoculated with the Flury strain of rabies virus which had been subjected to 138 successive passages by intracerebral inoculation in chicks followed by 64 passages in embryonated eggs. Medium 199 was added and the cells were cultured seven days at 35 DEG C.  The culture medium was frozen and thawed to release intracellular virus and the resulting mixture was centrifuged to separate cell debris.  The supernatant liquid was used to inoculate fresh tubes of culture tissue and the whole process repeated for 14 passages.  Ten limiting-dilution purification passages were then made using physiological saline solution.  To harvest the virus, the liquid is separated from the tissue culture. The residue is treated with a conventional virus vaccine stabilizer e.g. casein hydrolysate, an amino acid sugar mixture or a buffered sugar solution, frozen and thawed to rupture the tissue cells and release the virus.  The stabilizer liquid is decanted, pooled with the prior harvest of maintenance medium and centrifuged to remove cell debris and produce the vaccine. Temperature at propagation is 34 to 37 DEG C. and duration 4 to 14 days preferably 7 to 9 days.
PROBLEM TO BE SOLVED: To obtain the subject new compound having a peculiar fragrance, useful in the field of perfume and applicable to a wide range of uses such as perfumery and/or detergents comprising perfumed water, environmental fragrance, soap, lotion, shampoo. SOLUTION: This new compound is expressed by formula I [wherein, R is methyl or phenyl; Y is a (substituted) &lt;=10C hydrocarbon group; (n) is 1 or 2] and is e.g. 3-methyl-5-phenyl-cis-4-penten-1-ol. The compound of formula I is obtained e.g. by reacting a cyclic vinyl ether of formula II with a Grignard reagent of the formula RMgX (wherein, X is chlorine, bromine or iodine) in the presence of a triarylphosphine and a nickel compound and by the acylation of the resultant cis-unsaturated alcohol of formula III with a carboxylic acid (or its derivative) of the formula YCO2H. A perfume composition including the compound of formula I is also applicable to the perfuming of food, fiber, cloth, paper, coating materials, ink, plastics or the like.
PURPOSE:To obtain stable suspension-type preparation of rectal administration, by irradiating supersonics to melt mixture composed of drug hardly soluble to base material of suppository, base material of suppository and additive and uniformly suspending and dispersing. CONSTITUTION:A mixture composed of a drug hardly soluble to a fat-soluble and water-soluble base material of suppository, a base material of suppository and additive (e.g., surfactant, perfume, coloring matter or filler) is molten. Melting temperature is 40-60 deg.C in the case of fat-soluble base material and 60-80 deg.C in the case of water-soluble base material. Next, supersonic of 18-44kHZ frequency is irradiated to the molten mixture for &gt;=5min. Then, the mixture is charged into a suppository container by conventional method, cooled and shaped to afford the aimed preparation. Bromazepam or diclofenac sodium, etc., is used as a drug.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method and a composition for targetedly delivering a medicine to only a target cell.  &lt;P&gt;SOLUTION: The method and the composition are directed to enhancing immune response and decreasing vaccine efficacy through simultaneous or sequential targeting of specific immune system components. The specific immune system components (such as macrophage, dendritic cells, B cells and T cells) are each individually activated by component-specific immunostimulating agents. One of such component-specific immunostimulating agents is an antigen-specific, species-specific monoclonal antibody. Additionally, the invention relates to a method which depends upon in vitro conversion of blood-derived immune cells (such as macrophage and lymphocyte) and which is for in vitro production of the antigen-specific, species-specific monoclonal antibody. The effect of vaccine is reinforced by administering a composition containing the component-specific immunostimulating agents and other elements (such as an antigen or carrier particles such as colloid methos (gold)).  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:A nail beautifying cosmetic, containing a polyhydric alcohol and a protein as active constituents, capable of imparting sufficient moisture to the nail plate and exhibiting effect on prevention of drying for a long period and aiming at the repair of acquired damage of the nail plate and protection of normal nail plate. CONSTITUTION:A nail beautifying cosmetic containing 10-40wt%, preferably 10-30wt% polyhydric alcohol, e.g. ethylene glycol, dipropylene glycol, pentaerythritol, maltose or D-gluconic acid, and 0.0005-0.1wt%, preferably 0.01-0.07wt% protein, e.g. soybean protein, cow&#39;s milk casein, collagen or keratin, as active constituents. Although nail beautifying effect is not recognized in only the protein, the combination thereof with the polyhydric alcohol exhibits synergistic effect. The dosage form may be any one of a solution, solubilized, emulsified and powder dispersed systems, etc.
PROBLEM TO BE SOLVED: To obtain an excellent hair growth-stimulating agent by adding a specific substance and water to a raw material comprising chitosan powder obtained by deacetylating chitin. SOLUTION: Purified chitosan powder produced by deacetylating the shells of crabs, lobsters, prawns, etc., is mixed with L-ascorbic acid (vitamin C) powder and water. The mixture is kneaded into a gel-like product, or further mixed with water to produce an aqueous solution. Preferably, 4-8 pts.wt. of the chitosan, 2-8 pts.wt. of the L-ascorbic acid and approximately 200 pts.wt. of the water are compounded. When the purification degree of the chitosan is &lt;=90%, the chitin is dissolved on the deacetylation treatment. Therefore, the low pure chitosan can also be used for the hair-growing agent. When the mixture is the gel-like product, the hair growth-stimulating agent, of course, has the hair-growing effect, and is further convenient for dressing the hair because of wholly having a proper viscosity.
FIELD: medicine, chemical-pharmaceutical industry, pharmacy. SUBSTANCE: invention relates to the development of agents used in common cold for curative-prophylactic aims. The proposed agent comprises dry extracts of purple coneflower, Saint-John&#39;s-wort, wild rose and licorice root and also nutrient citric acid and special supplements. An agent can be made as syrup or granules. Testing the proposed agent in spring-autumn period showed good clinical results. Also the use of this agent is suitable in the proposed medicinal form. EFFECT: valuable medicinal properties of agent. 5 cl, 2 ex
A medical, educational, and home healthcare materials distribution system for enabling medical subscribers to provide the best available diagnosis-related products to clients. A patient/user enters the system by presenting to a medical subscriber, either in person or by other means, to receive a medically-informed recommendation. The recommendation may be an oral communication, order form, or a special prescription pad. The medical subscriber may make suggestions to the patient/user as to appropriate educational materials and medical products or may rely entirely on the distribution center of the system to correlate the patient&#39;s diagnosis to preselected educational materials and home medical assessment or monitoring products. The patient may personally place orders through the system or have them ordered by the medical office. The distribution center ships the materials to the patient by mail and sends documentation of the transaction to the patient&#39;s physician&#39;s office.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hair treatment composition so improved that enough curly hair-straightening power or wave-forming power is obtained.  &lt;P&gt;SOLUTION: This hair treatment composition contains (a) a sulfite salt and/or a hydrogensulfite salt in an amount of 0.01-8.0 wt.% and (b) a protein-denaturing agent in an amount of 25-60 wt.%. Further, the hair treatment composition is set to have a pH of 8.0-9.5. And, the sulfite salt and/or the hydrogensulfite salt contained in the composition are effective for reducing damage of the hair. Further, the hair-denaturing agent contained in the composition is effective for improving the curly hair-straightening power or the wave-forming power of the hair treatment composition.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To efficiently and readily provide a 4-campestenone-containing composition or a composition containing the 4-campestenone as an active ingredient, which have antiobesity activity.  &lt;P&gt;SOLUTION: A method for producing the 4-campestenone-containing composition includes culturing filamentous fungi in a solid medium that contains campesterol to convert the campesterol in the medium to the 4-campestenone, thus providing a filamentous fungi-fermented product having a conversion to 4-campestenone of 5 mass% or higher. The filamentous fungi are the filamentous fungi belonging to the genus Penicillium or the genus Aspergillus which has a conversion to the 4-campestenone of 5 mass% or higher. Wheat bran is used as the solid medium. The 4-campestenone-containing composition having the antiobesity activity, is obtained by the production method.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The invention encompasses methods of introducing biologically active peptide s into a host (particularly for vaccination or transitor y expression of a therapeutic peptide) or administration of polynucleotides wh ich operatively encode for the peptide. In most embodime nts, the polynucleotides are naked in the sense that they are neither complexed t o colloidal preparations such as liposomes or associated  with a genomic integrating vector. In one embodiment, the naked polynucleotides are  administered to host tissues which have a high concentr ation of antigen presenting cells in them relative to other host tissues. It is be lieved that the polynucleotides are taken up and express ed locally, systemically and/or at locations remote from their point of entry i n the host. In another embodiment, the polynucleotides e xpress peptides which are effective in retarding, treating and preventing age-assoc iated illnesses and loss of disease resistance in mammal s. In this embodiment, subtherapeutic levels of the peptides are expressed at appropria te stages of the host&#39;s development. Devices and composi tions for use in the methods of the invention are also described.
PURPOSE:To obtain a stable phospholipid emulsion in a high concentration, having a low viscosity, good fluidity and useful for fluid therapy, by removing a neutral lipid of natural lecithin to give an aqueous dispersion of purified phospholipid, adding a fat or oil and protein to the dispersion and homogenizing the resultant blend. CONSTITUTION:A neutral lipid is removed from natural lecithin by treatment with cold acetone, etc., to give purified lecithin containing &gt;=20wt% phosphatidyl choline (hereinafter abbreviated to PC). The resultant purified phospholipid is preferably dispersed in hot water at &gt;=80 deg.C to afford a 10-50wt% aqueous dispersion. 20-100wt% fat or oil, e.g. soybean oil, rapeseed oil, etc., and 0.1-40wt% protein, e.g. sodium caseinate, albumin, etc., heated at &gt;=80 deg.C are added and blended with the above-mentioned dispersion and homogenized under a high pressure to provide the aimed emulsion. The use of the fat or oil provides a dispersion of low viscosity and addition of the protein affords the stable emulsion.
Apparatus and methods are provided including a patch assembly ( 20 ) configured to deliver a substance through a subject&#39;s skin. A frame ( 26 ) surrounds at least in part an open portion of the patch assembly, such that a region of the skin is exposed through the open portion when the frame is placed on the skin. A substance support area ( 28 ) is foldably coupled to the frame at a foldable joint ( 27 ). A substance delivery area ( 23 ) is adapted to be placed in contact with at least a portion of the region of skin, by the substance support area being folded with respect to the frame. A stiffener ( 29 ), disposed on the substance support area between the foldable joint and the substance delivery area, is configured to facilitate the placement of the substance delivery area on the portion of the region of skin. Other applications are also described.
The invention discloses a radiotherapy protective ointment composed of pure traditional Chinese medicines. The radiotherapy protective ointment is prepared from the following raw materials in parts by weight: 20-22 parts of aloe, 12-14 parts of pseudo-ginseng, 5-7 parts of olive oil, 10-12 parts of dragon&#39;s blood, 18-20 parts of gromwell, 8-10 parts of elephant hide powder, 3-5 parts of fresh water pearl, 3-5 parts of multiflower knoweed stem, 2-4 parts of borneol, 10-12 parts of radix astragali, 5-7 parts of giant knotweed, 3-5 parts of radix rehmanniae and 1-3 parts of sesame oil. The product can be used before or after the radiotherapy, and has unexpected effects. By using the superior composition, the product improves the blood circulation of the whole body and partial body, and promotes absorption of the wound surface inflammation from the aspect of enhancing the immunity and regenerative capacity of organisms. By using multiple traditional Chinese medicinal materials as the monarch and minister components, the product has the effects of promoting tissue regeneration, enhancing immunity, promoting blood circulation and absorbing inflammatory wound surfaces. The clinical application over the years proves that the ointment has excellent curative effects on radioactive skin protection and injury therapy.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to method of obtaining fluorescent derivatives of dextrans intended for studying transport of biologically active substances through cell membranes and studying mechanisms of medication action at cell and subcell levels. Method of obtaining includes carrying out reaction of fluorescent dye with activated oxidised dextran with further purification of final product from admixtures by ultra filtration. As fluorescent dye used is fluorescein, as activating agent -1,1&#39;-carbonyldiimidasol, activation of oxidised dextran being carried out by addition of 1,1&#39;-carbonyldiimidasol in reaction mixture of oxidised dextran with fluorescein. ^ EFFECT: increase of method efficiency. ^ 5 cl, 3 ex
PURPOSE: To obtain a skin-cleansing composition in the form of an oil-inwater emulsion capable of mildly removing dead cell from the skin and especially suitable for a sensitive skin. CONSTITUTION: This skin-cleansing composition in the form of an oil-in-water emulsion comprises an emulsifier having &lt;=12 HLB value, preferably 6-12 HLB value and solid non-hydrophilic lipidic grains having &lt;=50 deg.C, preferably 30-45 deg.C melting point and containing a cleansing agent (e.g. grain flour, clay or cosmetic removing oil). The lipidic grains comprises at least one kind of substance selected from an 8-18C linear saturated fatty acid triglyceride, butter or solid fraction of a vegetable fatty substance and silicone wax and has preferably 50-2000 μm, especially preferably 630-1200 μm average diameter. The composition contains the lipidic grains in an amount of 0.5-10 wt.%, preferably 0.5-5 wt.% based on total weight of the composition. The composition is especially useful when a heat-sensitive active agent (e.g. vitamin) is formulated therein.
FIELD: veterinary. SUBSTANCE: this preparation is based on cucumarioside, summary fraction of triterpene glycosides derived from waste resulting from manufacture of Far-Eastern holothuria, Japanese cucumaria. This preparation should be subcutaneously administered in single dose of 1 mkg/kg of animal&#39;s body mass with 1 ml of physiological salt solution two weeks before actual start of heat and repeatedly administered in first half of pregnancy. Same single dose of disclosed preparation should be administered for prophylactic purposes. EFFECT: excellent results. 1 dwg
The invention provides a kidney maintenance and nephritis treatment medicine. The medicine contains bile, Rheum officinale, willow twigs, Pericarpium Arecae, Radix Ginseng Rubra and orange peel. The bile can be filtered bear&#39;s bile or pig&#39;s bile, Rheum officinale, willow twigs, Pericarpium Arecae, Radix Ginseng Rubra and orange peel are dried, and the dried materials are crushed to form powder. The obtained Rheum officinale powder covers the medicine. The medicine is prepared by concretely using 8-12g of bile, 8-12g of Rheum officinale, 8-12g of willow twigs, 8-12g of Pericarpium Arecae, 8-12g of Radix Ginseng Rubra and 8-12g of orange peel according to a ratio of 1:1:1:1:1:1:1. The medicine can effectively cure nephritis and can also nourish the kidney.